Advances in Bioreactor Design for Large Scale Production of Monoclonal Antibodies

Camille Laurent
University of Bordeaux, France

DOI:https://doi.org/10.5912/jcb2527

Abstract:

Advancements in bioproduction technologies for the large-scale manufacture of monoclonal antibodies (mAbs) has been transformed by innovation in bioreactor design as regards efficiency, scalability, and product quality. Modern bioreactors include cell culture performance improvement features in the form of real-time monitoring, automated control, and parameter settings. Furthermore, disposable bioreactors represent low-cost and flexible alternatives to stainless-steel systems, as they minimize contamination risks while lowering operational expenditures. Additionally, perfusion-based systems have enhanced productivity by keeping nutrients and waste at optimal concentrations. CFD and AI have further increased the efficiency of bioreactor operation by optimizing control over mixing, aeration, and shear forces. Together with hybrid and modular bioreactor systems, these advances, claim to simplify scale-up and integration of research results into commercial production processes. This paper examines modern advances in technological equipment for monoclonal antibodies production and focuses particularly on the development of novel bioreactors that facilitate mAb proliferation considering the increasing necessity of utilizing them for therapeutical determinations.